SCHEMBL9944197

SCHEMBL9944197

CC(=O)c1ccc(NC(=O)c2cc(Cl)c(OC(C)C)c(OC(C)C)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.52
TAS1R1 Q7RTX1 1/20 0.52
TAS1R2 Q8TE23 1/20 0.52
RORC P51449 1/20 0.50
TOP1 P11387 1/20 0.49
PLAU P00749 1/20 0.47
MAPT P10636 8/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPK1 P28482 1/20 0.46
RAB9A P51151 5/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
NPC1 O15118 4/20 0.46
KCNQ3 O43525 1/20 0.46
KCNQ2 O43526 1/20 0.46
KMT2A Q03164 5/20 0.44
POLB P06746 2/20 0.44
MEN1 O00255 4/20 0.43
HTT P42858 1/20 0.43
NLRP1 Q9C000 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944216 0.93 TAS1R3 (0.56) TAS1R3TAS1R1TAS1R2MAPTALDH1A1
SCHEMBL9944212 0.93 TAS1R3 (0.60) TAS1R3TAS1R1TAS1R2RORCTOP1
SCHEMBL9944177 0.92 TAS1R3 (0.57) TAS1R3TAS1R1TAS1R2RORCTOP1
SCHEMBL1458068 0.90 TAS1R3 (0.52) TAS1R3TAS1R1TAS1R2RORCTOP1
SCHEMBL9944214 0.90 MEN1 (0.52) TAS1R3TAS1R1TAS1R2RORCPLAU
SCHEMBL9944222 0.90 GAA (0.53) TAS1R3TAS1R1TAS1R2RORCPLAU
SCHEMBL9944193 0.88 RORC (0.49) TAS1R3TAS1R1TAS1R2RORCTOP1
SCHEMBL9944179 0.88 TAS1R3 (0.52) TAS1R3TAS1R1TAS1R2RORCTOP1
SCHEMBL9944248 0.87 RORC (0.51) RORCTOP1MAPTALDH1A1MAPK1
SCHEMBL9944254 0.86 SMN1; SMN2 (0.51) TOP1PLAUMAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG TAS1R3 1123/4885TAS1R1 693/4885TAS1R2 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.